ISIS Pharmaceuticals (ISIS) Results Called 'Stunning'

June 24, 2013 10:56 AM EDT Send to a Friend
BMO Capital today maintained an Outperform rating on ISIS Pharmaceuticals (NASDAQ: ISIS) with a price target of $31.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login